PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Some net income increase while AVXL is negative at -10.32%. John Neff would see a short-term edge over the struggling competitor.
3.11%
D&A growth well above AVXL's 0.40%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-10.59%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-5.75%
Negative yoy SBC while AVXL is 2.50%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
224.19%
Slight usage while AVXL is negative at -515.92%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
AP growth of 351.62% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-1034.42%
Both reduce yoy usage, with AVXL at -515.92%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-5.75%
Negative yoy while AVXL is 100.01%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.47%
Some CFO growth while AVXL is negative at -16.89%. John Neff would note a short-term liquidity lead over the competitor.
90.96%
CapEx growth of 90.96% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
We expand invests by 90.96% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-1.15%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-84.36%
Both yoy lines negative, with AVXL at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.